Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis.
Signaling of the C3a anaphylatoxin through its G protein-coupled receptor, C3aR, is relevant in a variety of inflammatory diseases, but its role in lupus nephritis is undefined. In this study, we show that expression of C3aR was significantly increased in prediseased and diseased kidneys of MRL/lpr lupus mice compared with MRL/+ controls. To investigate the role of C3aR in experimental lupus, a small molecule antagonist of C3aR (C3aRa) was administered continuously to MRL/lpr mice from 13 to 19 wk of age. All 13 C3aRa-treated mice survived during the 6-wk treatment compared with 9 of 14 (64.3%) control animals given vehicle (p = 0.019). Relative to controls, C3aRa-treated animals were protected from renal disease as measured by albuminuria (p = 0.040) and blood urea nitrogen (p = 0.021). In addition, there were fewer neutrophils, monocytes, and apoptotic cells in the kidneys of C3aRa-treated mice. C3aRa treatment also led to reduced renal IL-1beta and RANTES mRNA and phosphorylated phosphatase and tensin homologue deleted on chromosome 10 protein, whereas the mass of phosphorylated protein kinase B/Akt was increased by C3aRa. Thus, C3aR antagonism significantly reduces renal disease in MRL/lpr mice, which further translates into prolonged survival. These data illustrate that C3aR is relevant in experimental lupus nephritis and may be a target for therapeutic intervention in the human disease.
Bao
Lihua
L
Section of Nephrology, University of Chicago, Chicago, IL 60637, USA. lbao@medicine.bsd.uchicago.edu
Osawe
Iyabo
I
Haas
Mark
M
Quigg
Richard J
RJ
D000818:Animals; D000974:Antibodies, Antinuclear / Q000096:biosynthesis; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives; D001559:Benzhydryl Compounds / Q000008:administration & dosage; D015926:Complement C3a / Q000378:metabolism / Q000502:physiology*; D003169:Complement Inactivator Proteins / Q000008:administration & dosage; D019084:Fluorescent Antibody Technique, Indirect; D018836:Inflammation Mediators / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D019463:Mice, Inbred MRL lpr; D051059:PTEN Phosphohydrolase; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D012333:RNA, Messenger / Q000096:biosynthesis; D011951:Receptors, Complement / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology*; D025521:Tumor Suppressor Proteins / Q000378:metabolism; D015854:Up-Regulation / Q000235:genetics / Q000276:immunology*
D000974:Antibodies, Antinuclear; D001559:Benzhydryl Compounds; D003169:Complement Inactivator Proteins; D018836:Inflammation Mediators; D008565:Membrane Proteins; D012333:RNA, Messenger; D011951:Receptors, Complement; C431907:SB 290157; D025521:Tumor Suppressor Proteins; C085567:complement C3a receptor; D015926:Complement C3a; D001120:Arginine; D010744:Phosphoric Monoester Hydrolases; D051059:PTEN Phosphohydrolase